About C-C chemokine receptor type 6
C-C chemokine receptor type 6 (CCR6) is a protein
from Homo sapiens identified by UniProt accession
P51684, 374 residues long.
MolForge cross-references it against 0 known binders and
368 disease associations.
Target properties
| Protein name | C-C chemokine receptor type 6 |
| UniProt accession | P51684 |
| Gene | CCR6 |
| Organism | Homo sapiens |
| Length | 374 residues |
| Molecular weight | — |
| EC numbers | — |
| Target class | UNCLASSIFIED |
| Subcellular location | — |
| Keywords | — |
Druggability
Target tractability assessment (Open Targets + pocket analysis). No approved drug
| Druggability tier | MEDIUM |
| Druggability score | — |
| Pocket score | — |
| Max clinical phase | — |
Disease associations (368)
Diseases linked to this target (Open Targets).
- rheumatoid arthritis · score 0.47
- eosinophil count · score 0.41
- neurodegenerative disease · score 0.37
- ACPA-positive rheumatoid arthritis · score 0.37
- Immunosuppressant use measurement · score 0.36
- serum non-albumin protein measurement · score 0.35
- primary biliary cirrhosis · score 0.30
- total blood protein measurement · score 0.29
- albumin:globulin ratio measurement · score 0.28
- eosinophil percentage of leukocytes · score 0.28
3D Structure (1)
Experimental (PDB) and predicted (AlphaFold) structures for this protein.
| Structure | Source | Method | Mean pLDDT | Resolution (Å) |
| AF-P51684-F1 | alphafold | PREDICTED | 79.59 | — |
Amino-acid sequence (374 residues)
MSGESMNFSD VFDSSEDYFV SVNTSYYSVD SEMLLCSLQE VRQFSRLFVP IAYSLICVFG LLGNILVVIT FAFYKKARSM TDVYLLNMAI ADILFVLTLP FWAVSHATGA WVFSNATCKL LKGIYAINFN CGMLLLTCIS MDRYIAIVQA TKSFRLRSRT LPRSKIICLV VWGLSVIISS STFVFNQKYN TQGSDVCEPK YQTVSEPIRW KLLMLGLELL FGFFIPLMFM IFCYTFIVKT LVQAQNSKRH KAIRVIIAVV LVFLACQIPH NMVLLVTAAN LGKMNRSCQS EKLIGYTKTV TEVLAFLHCC LNPVLYAFIG QKFRNYFLKI LKDLWCVRRK YKSSGFSCAG RYSENISRQT SETADNDNAS SFTM
Explore C-C chemokine receptor type 6 with MolForge
Find binders, run structure-based screening, and map this target across
diseases and approved drugs with our AI-powered platform.
Browse all targets